SecBot SecBot
8-K ·Filed Sep 11, 2026

RNAZ

Transcode Therapeutics, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed1mo ago SEC0001104659-26-107115
8-K context-dependent: Items 5.02
Actionable Insight ▼ Bearish

The CFO departure at a micro-cap biotech with a $29M market cap is a negative signal, but the severance structure explicitly ties payments to the company raising $5M or $10M in funding, highlighting the company's urgent capital needs. Monitor for any 8-K regarding a financing transaction or SEPA drawdown, which would trigger additional severance payments and dilute existing shareholders.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d
RNAZ ▼ -1.21% at T+20d
SHORT call ✓ call won +1.21% · α vs SPY +3.48% · entry $1.65 → $1.63
Next anchor: T+60d in 6w
Latest observation: T+29 -86.92% FF3 residual α
Entry = T+0 close
Sep 11, 2026
via day close
T+1d
-3.03%
call +3.03% · α +2.57%
$1.60
settled 6w ago
T+5d
+6.67%
call -6.67% · α -6.56%
$1.76
settled 6w ago
T+20d
-1.21%
call +1.21% · α +3.48%
$1.63
settled 18d ago
T+60d
Pending
in 6w

Price Chart

Loading chart...

Executive Summary

TransCode Therapeutics CFO Thomas Fitzgerald resigned effective September 9, 2026, and was replaced by interim CFO John Tattory via a consulting arrangement with Stout Risius Ross. Fitzgerald received a separation agreement with up to $1.25M in severance, full vesting of outstanding equity, and a new option grant, with payments tied to the company raising $5M or $10M in qualified funding. The CFO departure at a $29M market cap micro-cap with no replacement named as a permanent employee is a negative signal, though the structured severance tied to fundraising milestones provides some transparency on the company's capital needs.

Key Facts

  • CFO Thomas Fitzgerald resigned effective September 9, 2026, and also left the board.
  • John Tattory appointed Interim CFO via consulting firm Stout Risius Ross at an hourly rate.
  • Separation agreement provides up to $1,250,000 in severance, including a $416,667 lump sum, $416,667 in monthly installments, and up to $416,667 additional payment tied to funding milestones.
  • All outstanding equity awards held by Fitzgerald become fully vested and exercise periods extended.
  • Fitzgerald received a new option to purchase 185,000 shares at the closing price on the separation date, vesting over 12 months.
  • Severance third payment and monthly installments are contingent on the company raising $5M or $10M in qualified funding within 12 months.
  • The company has a Standby Equity Purchase Agreement (SEPA) with an affiliate of Yorkville Global Advisors, which counts as qualified funding.
  • Fitzgerald's resignation was not due to any disagreement with the company on operations, policies, or practices.

Financial Impact

Up to $1.25M in severance cash payments plus accelerated equity vesting and a new 185,000-share option grant

cashdilution

Risk Factors

  • CFO departure creates operational uncertainty at a micro-cap development-stage company
  • Severance payments of up to $1.25M represent a material cash drain relative to the $29M market cap
  • Funding milestones in the severance agreement signal the company's need to raise capital, likely via dilutive financing or the Yorkville SEPA
  • New option grant of 185,000 shares adds potential future dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-107115
Document: tm2625146d1_8k.htm0001104659-26-107115
Document: 0001104659-26-107115-index-headers.html0001104659-26-107115
Document: 0001104659-26-107115-index.html0001104659-26-107115
Document: 0001104659-26-107115.txt0001104659-26-107115
10 reports for RNAZ
Performance horizon
80% Hit rate @ T+20 4 of 5 directional calls Went positive at some point 5 of 5 best @ T+20▲ +70.83%Jun 3, 2026
Filters
Rows
Reports for RNAZ — sortable, filterable
TypeNow
Sep 28, 2026
28d ago
8-K
BULLISH ★ 6/10
$1.71 $1.71▼ −0.26%▼ −0.23%$1.71 (−0.23%)
Sep 21, 2026
5w ago
3
NEUTRAL ★ 2/10
$1.77 $1.68▼ −5.08%▼ −4.52%$1.71 (−3.62%)
Sep 11, 2026
6w ago
8-K
BEARISH ★ 5/10
$1.65 $1.63▲ +1.21%▲ +3.48%$1.71 (−3.39%)
Jul 2, 2026
16w ago
8-K
NEUTRAL ★ 3/10
$8.61 $4.22▼ −50.99%▼ −51.84%$1.71 (−80.19%)
Jun 18, 2026
18w ago
8-K
NEUTRAL ★ 4/10
$4.70 $8.27▲ +75.96%▲ +75.42%$1.71 (−63.70%)
Jun 3, 2026
20w ago
8-K
BULLISH ★ 6/10
$5.04 $8.61▲ +70.83%▲ +71.83%$1.71 (−66.15%)
May 26, 2026
21w ago
DEFA14A
BEARISH ★ 6/10
$5.39 $4.94▲ +8.35%▲ +6.40%$1.71 (+68.35%)
Apr 30, 2026
25w ago
S-3
BEARISH ★ 8/10
$7.83 $5.44▲ +30.59%▲ +35.85%$1.71 (+78.21%)
Apr 7, 2026
28w ago
8-K
BEARISH ★ 7/10
$8.70 $7.74▲ +11.03%▲ +20.82%$1.71 (+80.39%)
Mar 3, 2026
33w ago
DEFA14A
MIXED ★ 6/10
$9.84 $8.69▼ −11.69%▼ −7.27%$1.71 (−82.66%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 4h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026